388622-47-7

Basic information

• Product Name: 5-Fluoro-6-hydroxy-naphthalene-1-carboxylic acid methyl ester
• Synonyms: 5-Fluoro-6-hydroxy-naphthalene-1-carboxylic acid methyl ester
• CAS NO: 388622-47-7
• Molecular Formula: C12H9 F O3
• Molecular Weight: 220.2
• Mol File: 388622-47-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Fluoro-6-hydroxy-naphthalene-1-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Fluoro-6-hydroxy-naphthalene-1-carboxylic acid methyl ester(388622-47-7)
• EPA Substance Registry System: 5-Fluoro-6-hydroxy-naphthalene-1-carboxylic acid methyl ester(388622-47-7)

Safety Data

• Hazardous Substances Data: 388622-47-7(Hazardous Substances Data)

Upstream product

• 90162-13-3 methyl 6-hydroxy-1-naphthoate 
• 1292322-36-1 C₁₂H₈F₂O₃ 
• 2437-17-4 6-hydroxy-1-naphthoic acid 
• 61109-48-6 6-methoxy-1-naphthalenecarboxylic acid methyl ester 

Downstream Products

• 847802-85-1 5-fluoro-6-hydroxy-1-naphthoic acid 
• 1292322-39-4 C₁₈H₁₄ClFO₂ 
• 1292322-40-7 5-fluoro-6-benzyloxy-7-chloronapthol-1 
• 1292322-45-2 C₅₅H₅₁ClF₂N₂O₂₃ 
• 1292322-48-5 C₅₉H₅₂Cl₂F₂N₂O₂₃ 
• 1292322-37-2 methyl 5-fluoro-6-benzyloxy-7-chloro-naphthoic ester 

Relevant articles and documents

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: Design, synthesis, and evaluation

A series of naphthyl-based compounds were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors. Investigations of structure-activity relationships led to the identification of a series of naphthamides that are potent inhibitors of the VEGF receptor tyrosine kinase family. Numerous analogues demonstrated low nanomolar inhibition of VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation, and of these several compounds possessed favorable pharmacokinetic (PK) profiles. In particular, compound 48 demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice. A full account of the preparation, structure-activity relationships, pharmacokinetic properties, and pharmacology of analogues within this series is presented.

Aniline pyrimidines, its preparation method and medical use (by machine translation)

The invention relates to: an aniline pyrimidine compound represented as the formula (I), a medicinal salt thereof, a prodrug thereof, and a hydrate or solvate thereof and also relates to: the preparation method of the compound, a medicine composition comp

NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF

The present invention relates to a naphthylamide compound of the structure as represented by formula (I), medicinal salts, prodrugs and hydrates or solvates thereof, and also relates to a method of preparing the compounds, pharmaceutical compositions comp

FLUORESCENT CALCIUM INDICATORS THAT ARE RATIOMETRIC AND EMIT IN THE RED SPECTRUM

A new generation of fluorescent ion indicators for measuring cytosolic concentrations of calcium. These new indicators emit in the red portion of the visible spectrum and are ratiometric. The ratiometry consists of shifting in the emission upon binding ca

Synthesis and photophysical properties of new fluorinated benzo[c]xanthene dyes as intracellular pH indicators

Two new fluorinated benzo[c]xanthene dyes were synthesized by reaction of fluorinated 1,6-dihydroxynaphthalenes with 2,4- (and 2,5)-dicarboxy-3′-dimethylamino-2′-hydroxybenzophenone. The two critical fluorinated 1,6-dihydroxynaphthalene intermediates were prepared via a regioselective route. The fluorinated benzo[c]xanthene dyes exhibit desired lower pKa values (6.4 and 7.2, respectively) than their parent compound (pKa = 7.5) while the pH-dependent dual-emission characteristics are well retained. Their cell-permeable esters have been prepared for intracellular applications.